Oil prices tied to Middle East risk are in focus again, which keeps inflation and interest rate expectations in play. That backdrop makes investors look harder at themes that do not rely only on cheap capital or broad economic momentum. Transformative AI healthcare stocks fit that search for structural growth drivers. This article highlights three stocks from the Transformative AI Healthcare Stocks screener that stand out for further research.
The three stocks below are a focused sample. The full screen surfaced 4 more AI healthcare companies with equally compelling narratives that are not covered here. If you want to go straight to the source and identify your own highest conviction AI healthcare ideas, analyze the Transformative Artificial intelligence (AI) Healthcare Stocks screener.
ImExHS (ASX:IME)
ImExHS is a Sydney based company that provides cloud based medical imaging software and outsourced radiology services to hospitals and clinics, with products covering radiology, cardiology and pathology workflows. It generated about A$10 million from software and A$19.2 million from radiology services, highlighting a business that blends recurring software with service revenues, largely tied to Latin American healthcare systems. With a market cap of roughly A$17.4 million, ImExHS sits firmly in micro cap territory, which can make both the potential upside and the risks more pronounced for investors.
ImExHS may appeal to investors who are looking for a smaller AI healthcare stock where software and services feed into each other. Aquila+ and other platforms are being used across Latin American radiology operations. At the same time, the company still reports losses, has higher risk external funding and relatively low board independence, and is now bedding in a new CFO and company secretary. For investors who can handle micro cap volatility, the mix of AI driven workflows, recurring software contracts and valuation metrics could make this a story worth watching more closely.
ImExHS sits at an interesting crossroads where recurring software meets radiology services, yet the market cap still prices it as a tiny outlier. Get the full story in the analysis report for ImExHS
Build your own AI healthcare shortlist around ImExHS
ImExHS and the two other stocks in this article all came from a single screen, but the real advantage is setting filters that match your own approach. Use our flexible Screener to mix valuation, growth and risk checks, or start with any of our curated Investing Ideas for ready made shortlists.
Singular Health Group (ASX:SHG)
Singular Health Group builds 3DiCom medical software that turns 2D scans into interactive 3D models, supports secure image sharing, and brings AI analysis into the cloud to help clinicians with diagnosis and treatment planning. The business currently generates about A$1 million in revenue from the provision and development of this medical technology, highlighting an early stage, product focused model. With a market cap of roughly A$60.2 million, Singular Health Group sits in the higher end of micro caps, where expectations around future adoption of its platform matter a lot.
Singular Health Group sits at the sharp end of AI driven medical imaging, with 3D visualization, AI in the cloud and new partnerships pointing to a clear product goal of faster and more informed radiology decisions. Yet revenue is still under A$1 million, the company is loss making with a declining earnings trend and a cash runway of less than a year, and funding relies on higher risk external borrowing. Investors who can tolerate volatility and short term funding risk may see the mix of advanced imaging technology, regulatory milestones and early hospital pilots as reasons to keep Singular Health Group on the watchlist for further research.
Singular Health Group’s 3D imaging story and A$60.2 million micro cap status can make early hospital pilots look more important than they seem. See how the analyst forecasts for Singular Health Group frame that trade off before funding risk shifts the picture.
Artrya (ASX:AYA)
Artrya is a Perth based medical technology company that uses artificial intelligence in its Salix software to detect and assess coronary artery disease from CT angiography scans, helping clinicians spot patients at risk of heart attack. The company currently generates around A$0.03 million from the development of its AI driven CCTA image analysis technology, all from Australia. At a market cap of roughly A$770.2 million, Artrya sits at the larger end of ASX listed AI healthcare stocks.
Artrya interests investors who want pure play exposure to AI driven cardiac imaging and who are comfortable with an early commercial stage story. The thesis focuses on a potential three module revenue model tied to CCTA scan volumes, supported by growing use of plaque assessment codes in the US and the large SAPPHIRE real world study that could build long term clinical proof points. On the other hand, revenue today is tiny compared with operating outflows, competitors in US cardiac imaging are well entrenched and shareholders have already experienced dilution and insider selling. A fresh CFO with deep radiology software experience joins from Pro Medicus later in 2026, which could be a meaningful test of how Artrya balances growth ambitions with cash discipline.
Artrya’s AI cardiac story and A$770.2 million size put it in a different league to most early stage peers, yet the real question is how future scan volumes and study data feed through its analyst forecasts for Artrya
Seeking Alternatives Before Momentum Flies
Fresh ideas move first. Stocks starting a breakout can be caught early, while weak stories keep dropping. Before the crowd catches up and information goes stale, consider acting sooner rather than later.
- Look for income opportunities with durability by scanning the 5 dividend fortresses, which targets reliable payouts while prices may still reflect hesitation instead of full confidence.
- Explore potential future leaders in automation by reviewing the curated 39 robotics and automation stocks, which groups companies involved in the machines and software used to support productivity.
- Identify companies with resilient balance sheets before momentum accelerates by filtering through the hand picked list of solid balance sheet and fundamentals (19 results), which highlights businesses designed to handle financial shocks.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com